Global spine biologics market generated revenue of $1,644 million in 2015, and is projected to reach $2,214 million by 2022, growing at a CAGR of 4.3% during the forecast period. Spine biologics are used during spine fusion surgery for the treatment of spinal deformities such as trauma, tumors, degenerative disc disease, and spinal cord injuries. Increase in geriatric population, advantages of biologics such as minimal postoperative time, faster recovery, and their ability to activate cellular growth are the factors that drive the market growth. However, unfavorable reimbursement scenario, higher cost of the bone grafts, and certain ethical issues related to bone grafting procedures are expected to restrain the growth of the market.
Biologics are used during spinal fusion procedure, as they stimulate bone growth formation through inflammatory stage, repair stage, and remodeling stage. Therefore, rise in number of spinal fusion surgery boosts the use of biologics.
Increase in geriatric population is the major factor anticipated to fuel the demand for biologics in future. For instance, spinal disorders such as spinal stenosis is the most common problem in men and women over 50 years. Aging leads to structural alterations in spine such as thickening of the band of the tissue that supports the spine and enlargement of bones & joints, thus resulting in spinal impairment. According to "Eurostat", the population of the European Union (EU) was estimated to be 508.5 million on January 1, 2015. Aged population (65 or over) had a share of 18.9%, which showed an increase of 0.4% compared to the previous year. Therefore, older people who are at a higher risk to develop spinal deformities have increased chances to undergo spinal fusion surgery, which in turn is projected to increase the demand for spine biologics.
Key Benefits of the Report
The study provides an in-depth analysis of the global spine biologics market with current trends and future estimations to elucidate the imminent investment pockets.
Quantitative analysis from 2014 to 2022 is expected to enable the stakeholders to capitalize on prevailing market opportunities.
The report provides actual historical figures for 2014 and Y-o-Y forecasts from 2016 to 2022, considering 2015 as base.
Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities in these geographies.
Extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the market framework.
Spine Biologics Market Key Segments
By Product
Spinal Allografts
Machined Bones Allograft
Demineralized Bone Matrix
Bone Graft Substitutes
Bone Morphogenetic Proteins
Synthetic Bone Grafts
Cell based Matrix
By Surgery
Open Spine Surgery
Minimally Invasive Spine Surgery
By Geography
North America
U.S.
Canada
Mexico
Europe
France
Germany
UK
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
